Application of Fibrin Associated with Photobiomodulation as a Promising Strategy to Improve Regeneration in Tissue Engineering: A Systematic Review

Carlos Henrique Bertoni Reis 1,2, Daniela Vieira Bachaim 3,4, Adriana de Cássia Ortiz 2, Simone Ortiz Moura Fideses 2, Jefferson Aparecido Dias 3,5, Maria Angelica Miglino 6, Daniel de Bortoli Teixeira 3,7, Eliana de Souza Bastos Mazuqueli Pereira 3, Marcelo Rodrigues da Cunha 8 and Rogerio Leone Buchaim 2,6,8 *

Abstract: Fibrin, derived from proteins involved in blood clotting (fibrinogen and thrombin), is a biopolymer with different applications in the health area since it has hemostasis, biocompatible and threedimensional physical structure properties, and can be used as scaffolds in tissue regeneration or drug delivery system for cells and/or growth factors. Fibrin alone or together with other biomaterials, has been indicated for use as a biological support to promote the regeneration of stem cells, bone, peripheral nerves, and other injured tissues. In its diversity of forms of application and constitution, there are platelet-rich fibrin (PRF), Leukocyte- and platelet-rich fibrin (L-PRF), fibrin glue or fibrin sealant, and hydrogels. In order to increase fibrin properties, adjuvant therapies can be combined to favor tissue repair, such as photobiomodulation (PBM), by low-level laser therapy (LLLT) or LEDs (Light Emitting Diode). Therefore, this systematic review aimed to evaluate the relationship between PBM and the use of fibrin compounds, referring to the results of previous studies published in PubMed/MEDLINE, Scopus and Web of Science databases. The descriptors “fibrin AND low-level laser therapy” and “fibrin AND photobiomodulation” were used, without restriction on publication time. The bibliographic search found 44 articles in PubMed/MEDLINE, of which 26 were excluded due to duplicity or being outside the eligibility criteria. We also found 40 articles in Web of Science and selected 1 article, 152 articles in Scopus and no article selected, totaling 19 articles for qualitative analysis. The fibrin type most used in combination with PBM was fibrin sealant, mainly heterologous, followed by PRF or L-PRF. In PBM, the gallium-aluminum-arsenide (GaAlAs) laser prevailed, with a wavelength of 830 nm, followed by 810 nm. Among the preclinical studies, the most researched association of fibrin and PBM was the use of fibrin sealants in bone or nerve injuries; in clinical studies, the association of PBM with medication-related treatments osteonecrosis of the jaw (MRONJ). Therefore, there is scientific evidence of the contribution of PBM on fibrin composites, constituting a supporting therapy that acts by stimulating cell activity, angiogenesis, osteoblast activation, axonal growth, anti-inflammatory and anti-edema action, increased collagen synthesis and its maturation, as well as biomolecules.
Keywords: tissue regeneration; fibrin; scaffolds; fibrin glue; fibrin sealant; platelet-rich fibrin; photobiomodulation; review; low-level laser therapy

1. Introduction

The word fibrin, in etymology, derives from the Latin ‘fibre’ (fiber) and –in (chemical substance). It can be defined as a protein formed in blood plasma from the action of thrombin on fibrinogen, being the main component of blood clots (that is, fibrin aggregating produces clots). Wound healing depends entirely on the initial mechanisms of tissue homeostasis. When an injury occurs, the first tissue to respond is blood, as bleeding is a potentially serious risk to the body. There is a cascade of molecular and cellular reactions that lead to the sealing of the vascular lesion with an aggregate of platelets, which stop the hemorrhage by forming a tampon in the injured tissue, triggering the next steps of tissue regeneration. Stable blood clot, containing cross-linked and polymerized fibrin, is essential to prevent bleeding and lead to wound repair after vascular injury [1,2].

Fibrin is a viscoelastic polymer and its mechanical and structural properties as a fibrin scaffold determine its effectiveness in hemostasis and in the development and outcome of thrombotic complications. Fibrin polymerization comprises a series of consecutive reactions, each affecting the final structure of the 3D porous network. Structural features in the fibrin molecule determine the physical properties of clots, and it is important for the blood clot to support arterial flow, clot contraction by platelets, and other dynamic forces [3,4].

The three-dimensional structure of fibrin allows for a series of cellular interactions and provides a temporary matrix in which cells can proliferate, organize, and perform their functions, especially at injured or inflamed sites. Thus, fibrin has been used with the aim of accelerating healing and regeneration in several surgical procedures, especially in medicine in the areas of orthopedics [5,6], neurology [7–9], and plastic surgery [10,11], as well as in dentistry in the areas of periodontics [12,13], implantology [14,15], and oral and maxillofacial surgery [16,17].

One of the ways to use fibrin in tissue regeneration is platelet-rich fibrin (PRF) which, unlike platelet-rich plasma (PRP), PRF has a high concentration of fibrin and white blood cells, not platelets. PRP and PRF have the same ability to accelerate the healing of soft and hard tissues by increasing the concentration of growth factors, but PRF acts to release growth factors over a longer period, providing longer lasting benefits, as well as stimulating a faster healing process than PRP [18]. PRF increases the concentration of these factors, among which we can exemplify the platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), factors which help to accelerate neovascularization and cell differentiation [18,19].

Studies also evaluate “fibrin glues” that can be called fibrin adhesive, fibrin sealant or fibrin biopolymer in tissue regeneration [20–23]. Human fibrin glue is manufactured using two components, one of which is a concentrate of clotting proteins (fibrinogen, fibronectin and Factor XIII) and the other is thrombin, both lyophilized. The first component is reconstituted with an aprotinin solution that inhibits tissue fibrinolysis. Thrombin is mixed with calcium chloride, thus being a grouping of substances participating in hemostasis and wound repair, giving the product properties such as hemostatic action, sealant and biological stimulation, which favor the formation of new tissue matrix [24,25]. In Brazil, a group of researchers from the Center for the Study of Venoms and Venomous Animals (CEVAP/UNESP Botucatu) developed and has been using in several studies, a fibrin sealant without the presence of derivatives from human blood, being totally heterologous, which has components derived from snake venom and fibrinogen from buffalo blood. This sealant, due to its diversity of use, is currently called fibrin biopolymer [8,26].

However, in view of the search for a rapid morphological and functional recovery of the injured tissues, more than one type of therapy can be combined (in this case, a set of
therapies complementary to the treatment). One of them is the low-level laser (LLLT), with tissue stimulation properties through red or infrared light with the ability to modulate the repair process, reducing pain, increasing tissue vascularization, promoting an increase in the production of mitochondrial ATP, and a series of biostimulatory effects, which led to the current name of photobiomodulation (PBM) therapy [27,28].

The combined use of fibrin glue with photobiomodulation has shown promising results in the repair of peripheral nerve injuries, being effective in the neurorrhaphy procedure, as well as providing a better quality of axonal regeneration to the interior of the distal stump [29]. In addition, this associated form of therapeutic use has demonstrated the ability to assist in the repair process of bone defects, stimulating angiogenesis and osteoblast proliferation, contributing to the formation of new bone in shorter postoperative periods and in greater volume [30].

However, there are still gaps in explaining the mechanisms of PBM therapy and its effects in combination therapies with fibrin. Therefore, this systematic review was designed from the PICO strategy (P: problem; I: intervention; C: control; O: outcome) [31,32], in order to analyze the relationship between PBM therapy and the use of fibrin compounds, such as PRF and fibrin sealants.

2. Materials and Methods

This systematic review was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, as well as other similar research [32–34]. For this, PubMed/MEDLINE, Scopus (Elsevier) and Web of Science databases were searched, with a specific search period (1 January 2002–30 April 2022), using the keywords: “fibrin AND low-level laser therapy” and “fibrin AND photobiomodulation”.

With the crossing of keywords, a detailed analysis of the results was carried out, being important in the selection the title and the abstract. From there, the manuscripts were separated into included and excluded according to the eligibility criteria. The authors carried out this process impartially and independently.

- Eligibility Criteria:
  The inclusion criteria were:
  • Therapeutic use of fibrin and PBM therapy as complementary therapy;
  • Studies in humans;
  • Studies in animals;
  • In vivo studies;
  • Case reports;
  • Publications only in English and that allowed full access to the text;
  • Each article included must present data on the PBM protocol.

- The exclusion criteria were:
  • Articles that were duplicated;
  • When the title had no connection to the objective;
  • Did not use fibrin;
  • Did not use photobiomodulation;
  • Used high power laser;
  • Other languages (except English);
  • When access to the full text was not obtained;
  • Incomplete data on the type of fibrin used.
  • Letters to the editor;
  • Review papers;
  • Commentaries;
  • Unpublished abstracts;
  • Dissertations or theses from repositories

Initially, the manuscripts with the title and abstract connected to the topic of the search were verified, with the terms: fibrin and PBM therapy, and then we evaluated and
restricted the articles only to the focus of the question in this review. Methodology, the results obtained, and the importance of these results were important to list the selected manuscripts. The selected articles on the topic were carefully read. In addition, two independent reviewers participated in the selection phases, ensuring that the inclusion and exclusion criteria were carefully followed, with the clear objective of minimizing bias.

Data related to the subject of this review were selected and extracted from the manuscripts by independent reviewers, taking into account the characteristics of the individual studies that contributed to their outcome as well as their aggregated results, without the objective of performing a meta-analysis.

The selection scheme, according to the PRISMA flow diagram [32,35,36], is shown in Figure 1.

Figure 1. Flow diagram showing study selection.

3. Results

The bibliography search found 44 articles in the PubMed/MEDLINE database, of which 26 were excluded since they were duplicates or due to inclusion/exclusion criteria. We also found 40 articles in Web of Science and selected 1 article, 152 articles in Scopus and no article selected, totaling 19 articles for qualitative analysis.

From the studies selected for a detailed description, we can see that, due to their physicochemical characteristics, fibrin compounds are widely used in several areas that mainly involve medicine and regenerative dentistry. In this way, three selected studies
were selected in which the researchers used hydrogels or 3D fibrin, 3 with L-PRF, 10 with fibrin sealants (or also called glue, adhesive or biopolymers) and 3 with autologous PRF (Figure 2).

**Type of fibrin presented by the selected and evaluated studies**

![Graph showing type of fibrin](image)

**Figure 2.** Configurations of fibrin preparations used in tissue regenerative processes. Three studies were used hydrogels or 3D fibrin, 3 with L-PRF, 10 with fibrin sealants (or also called glue, adhesive or biopolymers), and 3 with autologous PRF.

Regarding the results of photobiomodulation, we found (according to the eligibility criteria) three studies that used the red LED (Light Emitting Diode - original apparatus LDM-07 or Repuls Lichtmedizintechnik GmbH, Vienna, Austria), 1 infrared LED (original apparatus LDM-07), 1 GaAs (Gallium-Arsenide) laser (Fisioline; Lumix® C.P.S. Dental Multidiodic laser, Verduno, Cuneo, Italy), 10 GaAlAs (Gallium-Aluminum-Arsenide) laser (Laserpulse IBRAMED®, Amparo, Brazil), 2 ND: YAG (neodymium-doped: yttrium aluminium garnet) laser (Fotona, Ljubljana, Slovenia), 1 InGaAlP (Indium-Gallium-Aluminum-Phosphide) laser (MMOptics®, São Carlos, Brazil) and two studies did not identify the type of laser used (Figure 3).

**Type of PBM presented by the selected and evaluated studies**

![Graph showing type of PBM](image)

**Figure 3.** Type of photobiomodulation presented by the selected and evaluated studies. Gallium-Aluminum-Arsenide (GaAlAs) laser that presented greater use in the selected studies in tissue regenerative processes (10 studies). Two studies did not specify the type of PBM used. One study used different types of PBM, therefore considered separately in the data in the figure.
In the photobiomodulation protocols of the selected studies, when the wavelengths were analyzed, the most used was 830 nm, in nine studies. Then, 810 nm in three studies; 475 nm, 516 nm, 635 nm, and 1064 nm in two studies each; 633 nm, 650 nm, 660 nm, 840 nm, 910 nm with one study each; and one study did not disclose the wavelength used (Figure 4).

Figure 4. Protocols of PBM. Wavelength (nm) used by the studies included in Table 1. 830 nm that presented greater use in the selected studies in tissue regenerative processes (nine studies). One study did not present the wavelength used. Studies that used different wavelengths were considered separately in the data in the figure.

The articles selected to compose this review are presented in Table 1.
### Table 1. Articles that were selected for detailed analysis, following the eligibility criteria.

| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|--------------------------------------|------------------------|------------------------|-----------|-------|-------------|----------------|-------------|
| Bikmulina et al., 2020 [37] (PubMed) | LED light red and infrared (IR) (Original apparatus LDM-07) | Red: 633 and IR: 840 and Red: 160 ± 20 IR: 320 ± 40 | Red: 1.8 ± 0.2 and IR: 3.6 ± 0.4 | Red and IR: 2.2 ± 0.2 | Evaluation of PBM therapy for cell stimulation in hydrogels | Mesenchymal stromal cells (MSCs) obtained from human gingiva mucosa were encapsulated in fibrin (hydrogels) | A single exposure was made to low-intensity light, both red and infrared. After three days of culture, the physiological activity and viability of the cells were verified | The authors observed a dependence on cell viability in relation to the concentration of gel-forming proteins and the thickness of the hydrogels | Infrared light can be indicated for stimulation of MSCs proliferation and metabolism, in hydrogels with thicknesses of up to 3 mm |
| Tenore et al., 2020 [38] (PubMed) | Red and Infrared Gallium-Arsenide laser (GaAs) (Fisioline; Lumix® C.P.S. Dental Multidiodic laser) | Three wavelengths: 650, 810, 910 and G1: total power of 600 mW; G3 total power of 1100 mW | -/- | -/- | To evaluate the effect of three different protocols on the healing outcome in patients with established medication-related osteonecrosis of the jaw (MRONJ) | Leukocyte- and platelet-rich fibrin (L-PRF) | G1 was treated with antibiotic therapy, surgery, L-PRF and PBM; G2 with antibiotic therapy and surgery; G3 with antibiotic and PBM | There was no significant association between MRONJ results and location, stage, duration of drug treatment, diabetes, smoking, corticosteroid therapy, underlying disease, sex, and chemotherapy history at three and six months | The combination of antibiotic therapy, L-PRF, surgery and PBM can effectively contribute to the treatment of MRONJ |
| Buchaim et al., 2015 [29] (PubMed) | Gallium-Aluminum-Arsenide (GaAlAs) Laserpulse IBRAMED®, Amparo, Brazil | 830 and 30 | -/- | 4 | To analyze whether the fibrin adhesive allows, through end-to-side neurorrhaphy, the collateral growth of axons without an epineural window of the vagus nerve into a sural nerve graft and whether laser therapy contributes to the regeneration process | Fibrin glue derived from snake venom | Experimental Group (EG; n = 12 rats), sural nerve graft was coapted to the vagus nerve with fibrin glue; and experimental group laser (EGL; n = 12 rats), EG + LLLT and control group (CG; n = 8 rats), the intact sural nerve was collected | There was sprouting of axons from the vagus nerve into the autologous graft in the EG and EGL, and in the CG all of the dimensions measured were better, with a significant difference in relation to the EG and EGL, except for the area and thickness of the myelin sheath, which showed a significant difference only in relation to the EG | LLLT potentiates nerve regeneration and fibrin glue provided conditions for axonal regeneration in peripheral nerve injuries |
Table 1. Cont.

| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|--------------------------------------|------------------------|------------------------|-----------|-------|-------------|----------------|-------------|
| de Oliveira Gonçalves et al., 2016 [39] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 | 258.6 | 6 | To evaluate the effects of LLLT on an autogenous bone graft integration process stabilized with a new heterologous fibrin sealant (NHFS) | Heterologous fibrin sealant | Autogenous bone graft from rat calvaria, removed from the right parietal bone, with a 5 mm osteotomy, was adhered on the left side with fibrin sealant; groups: autogenous fibrin graft (AFG) and autogenous fibrin graft laser (AFGL), with the same procedures as the AFG, plus LLLT | The bone regeneration process was not complete, with new bone tissue partially integrating the graft into the recipient bed, with some areas of connective tissue. Morphometrically, minor interfaces occurred in the AFGL group, with significant differences in all analyzed periods | LLLT stimulated bone neoformation and improved the process of integration of autogenous bone graft |
| Buchaim et al., 2017 [40] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 | 258.6 | 6.2 | To analyze the efficacy of LLLT on quantitative, qualitative and functional aspects in the facial nerve regeneration | NHFS derived from snake venom | Suture experimental (SEG) and fibrin experimental (FEG) groups, the buccal branch of the facial nerve was sectioned, end-to-end epineural suture on the right side, and a NHFS on the left side; laser suture experimental (LSEG) and laser fibrin experimental (LFEG) groups, the same procedures as SEG and FEG with the addition of LLLT; control group (CG), facial nerve intact | LLLT resulted in a significant increase in the density and number of new axons. The LSEG and LFEG presented better scores in functional analysis in comparison with the SEG and FEG | Both repair techniques were effective in promoting axonal growth and LLLT improved these results, in addition to accelerating the functional recovery of whiskers |
| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|--------------------------------------|------------------------|------------------------|-----------|-------|-------------|----------------|-------------|
| Rohringer et al., 2017 [41] (PubMed) | LED lamps were provided by Repuls Lichtmedizintechnik GmbH, Vienna, Austria | Pulsed LED light of either 475 nm (blue), 516 nm (green), 635 nm (red) or remained unstimulated (control) | Peak irradiance intensity of 80 mW/cm² on all LED devices; average irradiance intensity of 40 mW/cm² | Dose 24 J/cm² (daily) | To compare the effects of PBM using light-emitting diodes (LED) with different wavelengths on endothelial cells in vitro | 3D fibrin matrices and fibrin gels | Migration and proliferation tests were performed in 2D and 3D. 3D fibrin gel co-culture model with human umbilical vein endothelial cells (HUVEC) and adipose-derived stem cells (ASC) was used to analyze early vasculogenic effects, continuous stimulation of LLLT, after one week of culture | Stimulation with green and red LED light increased 3D migration and proliferation of HUVEC. HUVEC also had greater potential for 2D migration with green light stimulation. Blue light was ineffective | Green light, in several parameters, has been shown to be more potent in stimulating endothelial cell migration and proliferation than red light |
| Priglinger et al., 2018 [42] (PubMed) | LED lamps were provided by Repuls Lichtmedizintechnik GmbH, Vienna, Austria | Pulsed LED light 475 nm (blue), 516 nm (green), 635 nm (red) | All LED devices had a peak irradiance intensity of 80 mW/cm² | Fluence of 24 J/cm² | To analyze the effects of green, blue and red light (RL) emitted by LEDs directly on freshly isolated SVF and analyzed cell phenotype, cell number, viability, ATP content, LDH cytotoxicity and proliferation, but also osteogenic, adipogenic and pro-angiogenic differentiation in vitro | 3D fibrin matrices | LLLT increased, compared to untreated cells, the colony-forming unit fibroblast assay with RL. The frequency of colony forming cells was not affected. LLLT with green light and RL resulted in a better potential to form vascular tubes by SVF compared to untreated cells when grown in 3D fibrin matrices | LLLT has beneficial effects in relation to SVF cell proliferation and vascularization potential. LLLT may represent a good method for clinical practice in activating SVF cells |
| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|---------------------|---------------------------------|-------------------------------------|------------------------|-----------------------|-----------|--------|-------------|----------------|-------------|
| Pomini et al., 2019 [43] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 | 258.6 | 6 | In rat calvaria (critical size defect—CSD), to evaluate the scaffold formed by a fibrin sealant (FS) plus xenograft associated with PBM therapy | Tisseel Lyo® (Baxter Healthcare Ltd., Norfolk, UK) | Bone neoformation was observed in all groups, limited to the defect margins. In the FSB group, new bone increased between periods (4.3 ± 0.46 to 6.01 ± 0.32), but with lower volume when compared to the FSB_PBM (5.6 ± 0.45 to 10.64 ± 0.97) | The biocomplex formed by the xenograft plus FS associated with the PBM therapy had a positive effect on the new bone formation |
| Hemaid et al., 2019 [44] (PubMed) | Diode Laser Gallium-Aluminum-Arsenide (GaAlAs) | 810 and 100 | -/- | 46.8 | To observe and compare the combined use of LLLT (810 nm), PRF and NanoHA in the healing of induced intraosseous periodontal defects | Autologous platelet-rich fibrin (PRF) | Sixteen defects in rabbits divided in four groups: laser irradiated control (CL); Control non-treated (C); PRF + NanoHA graft treated group and laser irradiated (NanoHA-Graft + PRF + L) | NanoHA-Graft + PRF + L showed significantly higher bone density in relation to the other groups | The best form of treatment was the combined use of LLLT + PRF + NanoHA as it presented the best results in the formation of new bone |
| Sahin et al., 2020 [45] (PubMed) | Nd: YAG laser (Fotona, Ljubljana Slovenia) | 1064 and 1250 | -/- | -/- | To analyze the surgical procedures used to prevent the development of MRONJ after dentoalveolar surgery in patients who received bisphosphonates | Leukocyte and platelet-rich fibrin (L-PRF) | Sixty-three surgeries were performed on forty-four patients taking bisphosphonate. Procedures: performed dentoalveolar surgical; antibiotics; fill the socket with L-PRF; LLLT (Nd: YAG Laser) | There were no intercurrences until cure. Complete mucosal healing occurred in all patients within one month with no long-term failures | The surgical protocol demonstrates promising results for the protection of MRONJ after performing dentoalveolar surgeries |
Table 1. Cont.

| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|---------------------------------------|------------------------|------------------------|-----------|-------|-------------|----------------|-------------|
| Thalaimalai et al., 2020 [46] (PubMed) | Diode laser | 810 and 500 | -/- | -/- | To evaluate the combined effect of LLLT and PRF, in site modulated intra-bony defects, which were accessed using a simplified papilla preservation flap (SPPF), on the periodontal disease | Autologous platelet-rich fibrin | Thirty patients with intra-bony defects (2 groups, n = 15 each). There was SPPF access at test group (TG) sites and defects received intramedullary penetration (IMP) after debridement, followed by LLLT and PRF grafting. In the control group (CG), the defects were accessed with SPPF and grafted only with PRF | TG showed a clinically relevant increase in mean probing pocket depth reduction, clinical attachment level gain, and radiographic bone fill compared to the CG, six months post-intervention | Together, LLLT with PRF caused an improvement in clinical and radiographic results within modulated intraosseous defects |
| Della Coletta et al., 2021 [47] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 | 258.6 | 6.2 | To evaluate the effects of PBM therapy on the guided bone regeneration process (GBR) in defects in the calvaria of rats filled with biphasic calcium phosphate (BCP) associated with fibrin | Fibrin biopolymer (FB) | Thirty Wistar rats: BMG, defects filled with biomaterial and covered by membrane; BFMG, biomaterial and fibrin biopolymer (FB) covered by membrane; and BFMLG, biomaterial and FB covered by membrane and biostimulated with PBM | There was more evident bone growth in the BFMLG, in addition to a progressive increase in new bone tissue in all groups, with a significant difference in the BFMLG, whose group presented greater bone neoformation in the periods of 14 and 42 days, followed by BFMG and BMG | PBM has been shown to be effective in improving and accelerating the GBR process when associated with BCP and FB |
| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm$^2$) | Energy Density (J/cm$^2$) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|--------------------------------------|---------------------------|--------------------------|-----------|--------|-------------|----------------|-------------|
| Sahin et al., 2021 [48] (PubMed) | Nd: YAG laser (Fotona, Ljubljana Slovenia) | 1064 and 1250 | -/- | -/- | To analyze the surgical technique described in the treatment of advanced stages of MRONJ patients | Autologous L-PRF concentrate | Twenty-one patients affected by Stage 2-3 MRONJ were treated with ultrasonic piezoelectric for bone surgery, with necrotic bone removing, L-PRF and LLLT | Two patients, who were Stage 3, had delayed healing at 1 month after surgery. Complete mucosal healing occurred in all patients in the third month | The surgical protocol shows promising results for surgical management of advanced stages of MRONJ patients |
| de Freitas Dutra Junior et al., 2021 [49] PubMed | Indium-Gallium-Aluminum-Phosphide laser (InGaAlP) (MMOptics®, São Carlos, Brazil) | 660 and 40 | 1000 | 6 | To verify, in tendon injuries, the action of the new heterologous fibrin biopolymer (HFB) associated or not with PBM | Heterologous fibrin biopolymer | Partial transection calcaneus tendon (PTCT) was performed in 84 rats divided into 4 groups: control (CG); HFB; PBM; HFB + PBM. HFB was applied immediately after PTCT, while PBM started 24 h after injury and continued every 24 h for 7, 14 and 21 days. | It can be noted that the reduction of edema was effective in the treatment groups when compared to the CG. In the periods of 14 and 21 days, PBM had a better repair process compared to GC | The HFB and PBM treatments, associated or isolated, promoted a reduction in the edema volume, favoring the repair process. HFB alone contributed more in promoting the tendon repair process |
| Buchaim et al., 2022 [50] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 | 258.6 | 6.2 | To analyze the effects of PBM on CSD filled with xenogenic bone substitute associated with HFB | Heterologous fibrin biopolymer (HFB) | CSD in 36 Wistar rats, four groups: BC and BC-PBM (controls) with defects filled by a clot (without or with PBM); XS and XS-PBM, filled with biocomplex Bio-Oss® + HFB. PBM was applied transoperatively and continued three times a week | BC-PBM and XS-PBM had a higher density of the bone neoformation in relation to the groups without PBM. Significant vascular proliferation and new bone deposition around the XS particles were observed in the animals which biocomplex (XS and XS-PBM) | PBM allowed an improvement in none neoformation, with a more organized deposition of collagen fibers. Biocomplex favored the permanence and insertion of the particulate biomaterial in bone defect |
Table 1. Cont.

| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|--------------------------------------|------------------------|------------------------|-----------|-------|-------------|----------------|------------|
| Rosso et al., 2017 [51] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 260 | 6.2 | New Heterologous Fibrin Sealant | Thirty-two rats, five groups: control (CG); experimental suture (ESG) and experimental fibrin (EFG) groups, end-to-side sutured to the zygomatic branch on the right side of the face or NHFS on the left side; experimental suture laser (ESLG) and experimental fibrin laser (EFLG) groups, with PBM | There was a significant difference in the fiber nerve area between the EFG and the EFLG. There was also faster functional recovery of the whisker movement in the ESLG and EFLG, where PBM was used, with results closer to the CG | Photobiomodulation with LLLT accelerated functional and morphological nerve repair, in both techniques |
| Rosso et al., 2020 [52] (PubMed) | GaAlAs (Laserpulse IBRAMED®, Amparo, Brazil) | 830 and 30 258.6 | 6 | Heterologous fibrin biopolymer (HFB) | Thirty rats, three groups. A noncritical bone defect of 2 mm was produced. Four Groups: (1) BM + PBMT; (2) BM + HFB; (3) BM + HFB + PBMT. In Groups 1 and 3 the animals were submitted to intraoperative PBM and every 48 h until the period of euthanasia | Statistical difference in bone neoformation between Groups 3 and 2 (26.4% ± 1.03% and 20.0% ± 1.87%, respectively) at 14 days and 42 days (38.2% ± 1.59% and 31.6% ± 1.33%, respectively). In 42 days there was presence of new bone with mature characteristics | The combined use of PBM with HFB and BM contributed to the process of reconstruction of non-critical bone defects |
Table 1. Cont.

| Reference (Database) | Type of Laser/LED (Manufacturer) | Wavelength (nm) and Output Power (mW) | Power Density (mW/cm²) | Energy Density (J/cm²) | Objective | Fibrin | Intervention | Outcome/Results | Conclusions |
|----------------------|----------------------------------|--------------------------------------|------------------------|-----------------------|-----------|-------|------------|----------------|-------------|
| Buchaim et al., 2016 [53] (PubMed) | GaAlAs (LaserPulse IRBAMED®, Amparo, Brazil) | 830 and 30 | 258.6 | 6 | To evaluate the effects of LLLT in the repair of the buccal branch of the facial nerve with two techniques: coaptation with HFS and end-to-end epineural suture | Heterologous fibrin sealant (HFS) | Forty-two rats, five groups: (1) control (CG), facial nerve (buccal branch) was collected without lesion; (2) experimental suture (EGS) and experimental fibrin (EGF) groups: end-to-end suture on the right side and HFS on the left side; (3) experimental suture laser (EGSL) and experimental fibrin laser (EGFL): plus LLLT | Axonal growth occurred in the distal stump of the facial nerve in all groups. The morphological aspect was similar to the GC fibers, with the majority of myelinated fibers. In the last period of the experiment, the EGSL presented the best results, being closer to the CG, in all measurements performed, except in the axon area | Laser therapy showed better results in facial nerve regeneration, being an effective technique to stimulate the repair process of peripheral nerve injuries |
| Doan et al., 2020 [54] (Scopus) | MLS laser (ASA laser, Vicenza, Italy) | -/- | -/- | 1.27 | Two clinical cases with piezoelectric surgery (PES), concentrated growth factors (CGF) and PBM, used in the search to increase the formation of new blood vessels and tissue repair after maxillary sinus lift surgeries with dental implants | Autologous concentrated growth factors (CGF) | The lateral sinus windows were created using PES. The implants were inserted in the same surgery and wrapped with CGF. A laser treatment of PBM was performed at the site, applied in the apical, buccal, lingual, coronal, mesial and distal regions of the surgical wound | Vascular budding and wound closure was observed after the first day. New bone formation was detected in the enlarged maxillary sinuses next to the implants, through radiographs and cone-beam computed tomography | PBM, PES, and CGF promoted the formation of new vessels, favored the approximation of the edges, closing the wound and reducing edema and bleeding. In addition, there was less postoperative pain, less use of analgesics and speech impairment, without trismus |
4. Discussion

This systematic review aimed to analyze published research on the association of photobiomodulation therapy, through the use of LLLT or LED, with fibrin scaffolds. The focus was on its use in tissue regeneration, mainly fibrin in the form of PRF and fibrin sealants (glues or adhesives) in order to verify the possible beneficial effects of PBM in three-dimensional fibrin scaffolds.

The initial description of fibrin comes from the classic coagulation cascade, proposed in 1964 by Macfarlane [55] and Davie and Ratnoff [56], documented in several articles. This model referred to as the “cascade” has been proposed to explain the physiology of blood clotting, whereby clotting occurs through sequential proteolytic activation of proenzymes by plasma proteases, resulting in the formation of thrombin, which then breaks down the fibrinogen molecule into fibrin monomers [57]. The fibrin network formed in the clot presents a particularly homogeneous and three-dimensional organization [58]. Furthermore, a progressive polymerization mode means increased incorporation of circulating cytokines in the fibrin meshes (intrinsic cytokines), providing an increase in the lifespan of these cytokines. Thus, cytokines are kept in situ for a convenient period when the scar cells begin to remodel the matrix, at which time they need to be stimulated to participate in the reconstruction of the injured site [59,60].

Due to its characteristics and properties, fibrin has been used in several areas, one of which is tissue regeneration in medical and dental procedures. Among the forms presented, in this review, three studies were selected for qualitative analysis that used hydrogels or 3D fibrin, 3 with L-PRF, 10 with fibrin sealants and 3 with autologous PRF (Figure 2). The production of autologous platelet concentrates (APCs) occurs by centrifuging the patient’s own blood, injecting isolated plasma, which is rich in growth factors. In tissue regeneration, two generations of APCs have been used: PRP, which are first generation, produced by double-spin centrifugation of blood; and PRF, the second generation, produced by single-spin centrifugation and has the fibrin matrix network intact. The effectiveness of platelet concentrates in promoting wound healing and tissue regeneration is at the center of recent academic discussion [61].

In a preclinical study, using LLT, PRF and Nano-HA nanohydroxyapatite graft (Fisiograft®, Ghimas, Italy) as variables, Hemaid et al., (2019) observed that the use of PRF + NanoHA mix results in an increase in bone fill and density regarding the radiographic outcomes in induced periodontal intrabony defects in rabbits, and LLLT may improve the results [44]. To prepare the PRF, five-milliliter blood samples were collected from each rabbit and then centrifuged at 30,000 × g RPM for 15 min. The PRF was separated into two pieces; one was used as a membrane and the other was cut into pieces to be added with Fisiograft® plus Nano-HA.

However, the study by Doan et al., (2020) the clinical applicability of the combination of autologous concentrated growth factors (CGF) and photobiomodulation (PBM) was made. Lateral sinus windows were created using piezoelectric surgery (PES) and the dental implants were concurrently fixated and wrapped with autologous fibrin (AF) rich CGF. Wound sites PBM treatment using a multiwave locked system laser. Bovine demineralized freeze-dried bone (Bio-Oss®, Chatswood, Australia) and hydroxyapatite and calcium triphosphate (Genoss®, Seoul, Korea) were incorporated into CGF for grafting. The application of AF offers benefits such as being a safe procedure, easy to perform and low cost [54] (Figure 5).

Three studies used L-PRF, developed in 2001 in France by Dr. Joseph Choukroun [62], during the production technique an attempt was made to accumulate platelets and release cytokines in a fibrin clot. This technique does not require anticoagulants, bovine thrombin or any other gelling agent, unlike other platelet concentrates; it is simply centrifuged natural blood without additives [58,63]. When using L-PRF, there are different methods and protocols in its production. In a pre-clinical study, in critical defects in the calvaria of rats, two methods of obtaining the concentrate were analyzed, by means of high (L-PRF) or low speed (A-PRF) centrifugation. The L-PRF and A-PRF groups had significantly higher bone
volume and newly formed bone area than the control group (clot only) and reduced bone porosity values, but with no significant difference between them in the histomorphometric and microtomographic analysis. Therefore, L-PRF and A-PRF potentiated the healing of critical defects, and high and low-speed centrifugation protocols did not produce PRF matrices with different biological impacts on the amount of new bone formation [64].

![Fibrin Applications in Tissue Engineering](image)

**Figure 5.** Schematic overview of fibrin applications in tissue regeneration. Fibrin is a plasma protein formed by the action of thrombin on fibrinogen, and constitutes a natural component of the blood coagulation cascade. The three-dimensional structure of the fibrin matrix serves as a natural scaffold that favors cell adhesion, migration, proliferation and differentiation, in addition to favoring the interaction with biomolecules and growth factors. Thus, fibrin has been used to promote tissue regeneration in various segments of medicine, in the form of sealants, hydrogels, PRF or L-PRF.

Leukocyte and platelet-rich fibrin (L-PRF) also have been used widely for bone tissue engineering. L-PRF has the potential to, in cases of bone loss, collaborate in osteogenic differentiation, increase osteoblast proliferation, tissue neovascularization and lower risk of local contamination [65,66]. The three studies in Table 1 that used L-PRF were combinations with PBM for the treatment of jaw osteonecrosis, all with good and promising results for use in the treatment of this type of bone disease [38,45,48]. Among the growth factors stored in platelets, which are essential for the tissue repair, are PDGF. Also present are VEGF-A, transforming growth factor-beta (TGF-β1), FGF-2, epidermal growth factor (EGF), hepatocyte growth factor (HGF), and insulin-like growth factor-1 (IGF-1) [67]. It should be taken into account the fact that L-PRF does not use the inclusion of anticoagulant and activating agents (CaCl₂) to obtain the platelet concentrate. The inclusion of these agents and activators, in addition to hard-centrifugation (≥210 g), can affect the amount and quality of platelet recovery and growth factor release, which can significantly influence healing behavior compared to natural fibrin clotting [68].

Three studies were used hydrogels or 3D fibrin [37,41,42], associated with PBM, being incorporated into the fibrin matrix endothelial cells [41], stromal vascular fraction (SVF) and mesenchymal stromal cells (MSCs) isolated from human gingival mucosa [37]. These studies agree that photobiomodulation combined with fibrin enhances the improvement of results, collaborating in cell and vascular proliferation.
Fibrin sealants were most commonly used in combination with PBM, in ten studies [29,39,40,43,47,49–53]. One of the studies used the fibrin sealant derived from human plasma (Tisseel Lyo® (Baxter Healthcare Ltd., Norfolk, UK) [43] and the others a heterologous fibrin sealant (HFS). This bioproduct (HFS) is composed of a thrombin-like enzyme purified from the venom of Crotalus durissus terrificus snake and a cryoprecipitate rich in fibrinogen extracted from Bubalus bubalis buffaloes (produced by CEVAP/UNESP—Center for the Study of Venoms and Venomous Animals, Botucatu, Brazil). HFS has several advantages in its use, such as a fast production process, low cost, potential to act as a scaffold for stem cells [69–71] and biomaterials [50,72], and as a new drug delivery system [73]. Its indications are in medical, veterinary and dental practice, due to the possibility of personalized formulation and replacement of conventional sutures. Considering all of the properties described for this bioproduct, which go beyond the adhesive capacity, the name “sealant” was reconsidered, and it has recently been called “fibrin biopolymer” [74,75].

In order to improve the tissue repair process, studies in the area of regenerative science seek the association of different therapies to accelerate and improve morphological recompensation and faster functional recovery. Among these conjunctions, light-based therapies, such as the use of low-power lasers and LEDs, have expanded their use in clinical and pre-clinical practices. The laser consists of a pure and well-defined color, while the LED can display different shades of colors at once. Therefore, the laser is a monochromatic light (only a well-determined color) and the LED is a polychromatic light, being able to present all of the shades of a specific color. Currently called photobiomodulation (PBM), consists of the application of light (Laser or LED) with therapeutic effect for tissue modulation (activation or inhibition). It has important potentialities such as angiogenesis and neovascularization [76], increase in collagen production [77], increase in muscle regeneration and decrease in its atrophy [78], favors nerve regeneration [9,79], increases cartilage production [80], and decreases inflammation, edema and pain [81] (Figure 6).

**Figure 6.** Schematic overview of beneficial properties of photobiomodulation therapy in regenerative medicine. The application of laser therapy favors angiogenesis, collagen synthesis, mitochondrial ATP production, cytokines and growth factors synthesis, in addition to inducing cell proliferation and differentiation. Additionally, photobiomodulation therapy has anti-inflammatory, analgesic and biostimulating effects, acting mainly in the initial stages of tissue healing.
In the studies selected for Table 1, according to the eligibility criteria, three used the red LED, 1 infrared LED, 1 GaAs laser, 10 GaAlAs laser, 2 Nd: YAG laser, 1 InGaAlP laser and two studies did not identify the type of laser used (Figure 3). Handler et al. (2021) carried out a study to investigate the effects of photobiomodulation at wavelengths of 660 nm (Aluminium-gallium-indium-phosphide laser, AlGaInP) and 830 nm (Arsenide-Gallium-Aluminum laser, AsGaAl) at different numbers of application points on the healing of open wounds in mice. Photobiomodulation with total energy of 3.6 J was applied at 1, 4, 5 and 9 points for 14 days. When comparing the photobiomodulation wavelength, the 830 nm (AsGaAl) groups were more effective, and the groups irradiated at 5 points stand out, which showed improvement in macroscopic analysis and epidermis thickness, increased number of vessels and lower number of fibroblasts on the 14th day after the skin lesion [82].

Regarding the wavelength, the most used was 830 nm, in nine studies. Then 810 nm in three studies; 475 nm, 516 nm, 635 nm, and 1064 nm in two studies each; 633 nm, 650 nm, 660 nm, 840 nm, and 910 nm with one study each; and one study did not disclose the wavelength used (Figure 4). A study conducted by Ma et al. (2018), to determine the effect of low-level laser therapy (LLLT) on diabetic wound healing and confirm its effect on the activity of healthy human fibroblasts, used PBM with an 830 nm (IR) wavelength, 635 nm (Red) and 635 nm + 830 nm (FX) with the same fluency of 60 J/cm². Irradiation in the FX and IR groups showed a significant increase in fibroblast proliferation and collagen synthesis compared to the control and RED groups. However, there was no significant difference in collagen synthesis and fibroblast proliferation between the FX group and the IR group. These data allowed the authors to conclude that healthy human fibroblasts showed better cell proliferation and collagen synthesis when irradiated at the wavelength of 635 nm + 830 nm or 830 nm [83].

The use of LED photobiomodulation is more recent than laser therapy. Current research advances in the evaluation of the separate or combined use of the two therapies in tissue repair. Doses ranging from 0.1 to 10 J/cm² and wavelengths from 405 to 1000 nm promote therapeutic benefits in tissue regeneration. Ranges of light energy sources, from lasers to LEDs, have been used and have specific advantages and limitations. There is no consensus on standardized treatment parameters such as wavelengths, therapeutic outcomes and doses, which limits direct comparison and clinical protocol recommendation [84–90].

The use of combined therapies that involve the use of fibrin associated with photobiomodulation therapy has shown to be a promising strategy to favor the regeneration of injured tissues with better quality and less time. When fibrin is applied to the lesion site, it forms a bioactive matrix in the microenvironment that exerts a hemostatic effect, in addition to favoring interactions between cells and biomolecules (Figure 7). These effects, added to those of PBM, constitute a supporting therapy that acts by stimulating cell activity, angiogenesis, and the synthesis of collagen and biomolecules [49,91–100].

In this review, among preclinical studies, the most researched association of fibrin and photobiomodulation was the use of fibrin sealants in bone or nerve injuries. In clinical studies, the association of PBM with medication-related treatments osteonecrosis of the jaw (MRONJ). All experimental protocols concluded that the association is effective; promoting a more effective repair of lesions, in a shorter period of time and with effectiveness that can reinforce the indication of its use. In peripheral nerves, PBM therapy accelerated morphological and functional nerve repair. In bone tissue [51], PBM allowed for an improvement in the formation of new bone, with a more organized deposition of collagen fibers in the defect area [50]; and in osteonecrosis of the jaw, PBM may effectively contribute to MRONJ management [38,45,101].

In this way, we can see that few studies used the association fibrin + PBM, but given the good results, the technique is promising, with the potential to collaborate in tissue repair. The difficulty in comparing the different types of PBM can be considered as a limitation, due to the different protocols reported in the experiments. Therefore, protocols with favorable results are generally standardized and reused by the same researchers in an
attempt to reduce this limitation. In addition, the scarcity of randomized clinical trials in the scope of this review can also be considered a limitation.

Tissue Engineering Strategies using Fibrin Scaffolds in Combination with Photobiomodulation Therapy (PBMT)

Figure 7. The application of fibrin combined with photobiomodulation therapy constitutes a promising strategy to favor regeneration in tissue engineering. Fibrin applied to the injury site forms a bioactive matrix that exerts a hemostatic effect, in addition to favoring interactions between cells and biomolecules. Photobiomodulation constitutes a coadjuvant therapy that acts by stimulating cell activity, angiogenesis and the synthesis of collagen and biomolecules. Thus, the application of fibrin associated with photobiomodulation therapy may have a beneficial effect, accelerating tissue healing.

5. Conclusions

This review was designed and carried out with the objective of analyzing studies, both clinical and pre-clinical, that used the association of photobiomodulation and fibrin. This association occurs with the purpose of tissue regeneration, in the search for its possible beneficial effects on morphophysiological and functional rehabilitation. The fibrin matrix, with its three-dimensionality, is a natural scaffold, which enables events that favor the repair of injured tissues, which is desired in tissue engineering procedures, through adhesion, migration, proliferation, and cell differentiation, in addition to contributing to the interaction with biomolecules and local tissue growth factors.

In the findings of this study, it can be shown that PBM contributed to improve tissue regeneration that used fibrin composites as scaffolds, constituting an important adjuvant therapy that acts by stimulating cell activity, angiogenesis, osteoblastic activation, axonal growth, anti-inflammatory and anti-edema action, increased collagen synthesis and its maturation, as well as biomolecules. More studies should be carried out in order to seek standardization in PBM protocols, in the same way that new fibrin concentrates will be developed with the same objective of recovering injured organs and tissues.
Author Contributions: Conceptualization, C.H.B.R., D.V.B. and R.L.B.; methodology, A.d.C.O. and S.O.M.F.; software, D.d.B.T.; validation, J.A.D.; formal analysis, M.R.d.C.; investigation, C.H.B.R. and R.L.B.; resources, M.A.M.; data curation, D.d.B.T. and M.R.d.C.; writing—original draft preparation, C.H.B.R., R.L.B. and D.V.B.; writing—review and editing, C.H.B.R. and R.L.B.; visualization, E.d.S.B.M.P.; supervision, R.L.B.; project administration, R.L.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Vilar, R.; Fish, R.J.; Casini, A.; Neerman-Arbez, M. Fibrin(ogen) in human disease: Both friend and foe. Haematologica 2020, 105, 284–296. [CrossRef] [PubMed]
2. Jahani-Sherafat, S.; Mokmeli, S.; Rostami-Nejad, M.; Razzaghi, Z.; Tavirani, M.R.; Razzaghi, M. The Effectiveness of Photobiomodulation Therapy (PBMT) in COVID-19 Infection. J. Lasers Med. Sci. 2020, 11, S23–S29. [CrossRef] [PubMed]
3. Litvinov, R.I.; Pieters, M.; de Lange-Loots, Z.; Weisel, J.W. Fibrinogen and Fibrin. In Macromolecular Protein Complexes III: Structure and Function. Subcellular Biochemistry; Springer: Berlin/Heidelberg, Germany, 2021; pp. 471–501.
4. Reddy, M.S.B.; Ponnamma, D.; Choudhary, R.; Sadasivuni, K.K. A comparative review of natural and synthetic biopolymer composite scaffolds. Polymers 2021, 13, 1105. [CrossRef] [PubMed]
5. Wang, M.; Gao, W. Fixation of platelet-rich plasma and fibrin gels on knee cartilage defects after microfracture with arthroscopy. Int. Orthop. 2022, 474. [CrossRef]
6. Grecu, A.F.; Reclaru, L.; Ardelean, L.C.; Nica, O.; Ciucă, E.M.; Ciurea, M.E. Platelet-rich fibrin and its emerging therapeutic benefits for musculoskeletal injury treatment. Medicine 2019, 55, 141. [CrossRef]
7. Vasilikos, I.; Beck, J.; Ghanaati, S.; Grauvogel, J.; Nisyrios, T.; Grapatsas, K.; Hubbe, U. Integrity of dural closure after autologous platelet rich fibrin augmentation: An in vitro study. Acta Neurochir. 2020, 162, 737–743. [CrossRef] [PubMed]
8. Buchaim, D.V.; Cassaro, C.V.; Shindo, J.V.T.C.; Coletta, B.B.D.; Pomini, K.T.; De Oliveira Rosso, M.P.; Campos, L.M.G.; Ferreira, R.S.; Barraviera, B.; Buchaim, R.L. Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: A systematic review. J. Venom. Anim. Toxins Incl. Trop. Dis. 2019, 25, 1–15. [CrossRef]
9. Rosso, M.P.d.O.; Buchaim, D.V.; Kawano, N.; Furlanette, G.; Pomini, K.T.; Buchaim, R.L. Photobiomodulation therapy (PBMT) in peripheral nerve regeneration: A systematic review. Bioengineering 2018, 5, 44. [CrossRef]
10. Gentile, P.; Calabrese, C.; De Angelis, B.; Dionisi, L.; Pizzicannella, J.; Kothari, A.; De Fazio, D.; Gargovich, S. Impact of the different preparation methods to obtain autologous non-activated platelet-rich plasma (A-PRP) and activated platelet-rich plasma (AA-PRP) in plastic surgery: Wound healing and hair regrowth evaluation. Int. J. Mol. Sci. 2020, 21, 431. [CrossRef]
11. Bressan, E.; Favero, V.; Gardin, C.; Ferroni, L.; Iacobellis, L.; Favero, L.; Vinidagini, V.; Berengo, M.; Sivolella, S.; Zavan, B. Biopolymers for Hard and Soft Engineered Tissues: Application in Odontoiatric and Plastic Surgery Field. Polymers 2011, 3, 509–526. [CrossRef]
12. Pepelassi, E.; Deligianni, M. The Adjunctive Use of Leucocyte-and Platelet-Rich Fibrin in Periodontal Endosseous and Furcation Defects: A Systematic Review and Meta-Analysis. Materials 2022, 15, 2088. [CrossRef] [PubMed]
13. Caramês, J.M.M.; Vieira, F.A.; Caramês, G.B.; Pinto, A.C.; Francisco, H.C.O.; Marques, D.N.D.S. Guided Bone Regeneration in the Edentulous Atrophic Maxilla Using Deproteinized Bovine Bone Mineral (DBBM) Combined with Platelet-Rich Fibrin (PRF)—A Prospective Study. J. Clin. Med. 2022, 11, 894. [CrossRef] [PubMed]
14. Jung, M.H.; Lee, J.H.; Wadhwa, P.; Jiang, H.B.; Jang, H.S.; Lee, E.S. Bone regeneration in peri-implant defect using autogenous tooth biomaterial enriched with platelet-rich fibrin in animal model. Appl. Sci. 2020, 10, 1939. [CrossRef]
15. Tallarico, M.; Xhanari, E.; Lumbau, A.M.I.; Alushi, A.; Ieria, I.; Fiorillo, L.; Fanà, F.; Meto, A.; Baldoni, E.; Meloni, S.M.; et al. Histological and histomorphometric evaluation of post-extractive sites filled with a new bone substitute with or without autologous platelet concentrates: One-year randomized controlled trial. Materials 2022, 15, 254. [CrossRef]
16. Li, Q.; Reed, D.A.; Min, L.; Gopinathan, G.; Li, S.; Dangaria, S.J.; Li, L.; Geng, Y.; Galang, M.T.; Gajendrareddy, P.; et al. Lyophilized Platelet-Rich Fibrin (PRF) promotes craniofacial bone regeneration through Runx2. Int. J. Mol. Sci. 2014, 15, 8509–8525. [CrossRef]
17. Zumaran, C.C.; Parra, M.V.; Olate, S.A.; Fernandez, E.G.; Munoz, F.T.; Haidar, Z.S. The 3 R’s for platelet-rich fibrin: A “super” tri-dimensional biomaterial for contemporary naturally-guided oro-maxillo-facial soft and hard tissue repair, reconstruction and regeneration. Materials 2018, 11, 1239. [CrossRef]
18. Almeida Barros Mourão, C.F.D.; Valiense, H.; Melo, E.R.; Freitas Mourão, N.B.M.; Maia, M.D.C. Obtenção da fibrina rica em plaquetas injetável (I-PRF) e sua polimerização com exereto ósseo: Nota técnica. Rev. Col. Bras. Cir. 2015, 42, 421–423. [CrossRef]
42. Priglinger, E.; Maier, J.; Chaudary, S.; Lindner, C.; Wurzer, C.; Rieger, S.; Redl, H.; Wollbank, S.; Dangel, P. Photobiomodulation of freshly isolated human adipose tissue-derived stromal vascular fraction cells by pulsed light-emitting diodes for direct clinical application. J. Tissue Eng. Regen. Med. 2018, 12, 1352–1362. [CrossRef]

43. Pomini, K.T.; Buchaim, D.V.; Androvo, J.C.; Rosso, M.P.; Della Coletta, B.B.; German, I.J.; Biguetti, A.C.C.; Shinohara, A.L.; Rosa Júnior, G.M.; Shindo, J.V.T.C.; et al. Fibrin sealant derived from human plasma as a scaffold for bone grafts associated with photobiomodulation therapy. Int. J. Mol. Sci. 2019, 20, 1761. [CrossRef]

44. Hemaid, S.; Saafan, A.; Hosny, M.; Wimmer, G. Enhancement of healing of periodontal intrabony defects using 810 nm diode laser and different advanced treatment modalities: A blind experimental study. Open Access Maced. J. Med. Sci. 2019, 7, 1847–1853. [CrossRef]

45. Şahin, O.; Tatar, B.; Ekmeckiçioğlu, C.; Aliyev, T.; Odabaşı, O. Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience. J. Clin. Exp. Dent. 2020, 12, e771–e776. [CrossRef]

46. Thalaimalai, D.B.R.; Victor, D.J.; Prakash, P.S.G.; Subramaniam, S.; Cholan, P. Effect of Low-Level Laser Therapy and Platelet-Rich Fibrin on the Treatment of Intra-bony Defects. J. Lasers Med. Sci. 2020, 11, 456–463. [CrossRef]

47. Della Coletta, B.B.; Jacob, T.B.; Moreira, L.A.d.C.; Pomini, K.T.; Buchaim, D.V.; Eleutério, R.G.; Pereira, E.d.S.B.M.; Roque, D.D.; Rosso, M.P.d.O.; Shindo, J.V.T.C.; et al. Photobiomodulation Therapy on the Guided Bone Regeneration Process in Defects Filled by Biphasic Calcium Phosphate Associated with Fibrin Biopolymer. Molecules 2021, 26, 847. [CrossRef]

48. Şahin, O.; Akar, E.; Tatar, B.; Ekmeckiçioğlu, C.; Ünal, N.; Odabaşı, O. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz. J. Otorhinolaryngol. 2022, 88, 613–620. [CrossRef]

49. de Freitas Dutra Júnior, E.; Hidd, S.M.C.M.; Amaral, M.M.; Filho, A.L.M.M.; Assis, L.; Ferreira, R.S.; Barraviera, B.; Martignago, C.C.S.; Figueiredo-Silva, J.; de Oliveira, R.A.; et al. Treatment of partial injury of the calcaneal tendon with heterologous fibrin biopolymer and/or photobiomodulation in rats. Lasers Med. Sci. 2022, 37, 971–981. [CrossRef] [PubMed]

50. Buchaim, D.V.; Andreo, J.C.; Pomini, K.T.; Barraviera, B.; Ferreira, R.S.; Duarte, M.A.H.; Alcalde, M.P.; Reis, C.H.B.; de Bortoli Teixeira, D.; de Souza Bueno, C.R.; et al. A biocomplex to repair experimental critical size defects associated with photobiomodulation therapy. J. Venom. Anim. Toxins Incl. Trop. Dis. 2022, 28, 1–14. [CrossRef] [PubMed]

51. Rosso, M.P.d.O.; Rosa Júnior, G.M.; Buchaim, D.V.; German, I.J.S.; Pomini, K.T.; de Souza, R.G.; Pereira, M.; Favaireto Júnior, L.A.; Bueno, C.R.d.S.; Gonçalves, J.B.d.O.; et al. Stimulation of morphofunctional repair of the facial nerve with photobiomodulation, using the end-to-side technique or a new heterologous fibrin sealant. J. Photochem. Photobiol. B Biol. 2017, 175, 20–28. [CrossRef]

52. de Oliveira Rosso, M.P.; Oyadomari, A.T.; Pomini, K.T.; Coletta, B.B.D.; Shindo, J.V.T.C.; Júnior, R.S.F.; Barraviera, B.; Cassaro, C.V.; Buchaim, D.V.; Teixeira, D.d.B.; et al. Photobiomodulation therapy associated with heterologous fibrin biopolymer and bovine bone matrix helps to reconstruct long bones. Biomolecules 2020, 10, 383. [CrossRef]

53. Buchaim, D.V.; Rodrigues, A.C.; Buchaim, R.L.; Barraviera, B.; Junior, R.S.F.; Junior, G.M.R.; Bueno, C.R.S.; Roque, D.D.; Dias, D.V.; Dare, L.R.; et al. The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve. Lasers Med. Sci. 2016, 31, 965–972. [CrossRef] [PubMed]

54. Doan, N.V.; Huynh, T.Q.; Tran, S.; Wang, G.; Hamlet, S.; Dau, V.; Dao, D.; Nguyen, N.T.; Nguyen, H.T.; Doan, J.; et al. Multidisciplinary approach to maximize angiogenesis and wound healing using piezoelectric surgery, concentrated growth factors and photobiomodulation for dental implant placement surgery involving lateral wall sinus lift: Two case reports. Vasc. Cell 2020, 12, 2. [CrossRef]

55. Macfarlane, R.G. An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier. Nature 1964, 202, 498–499. [CrossRef]

56. Davie, E.W.; Ratnoff, O.D. Waterfall sequence for intrinsic blood clotting. Waterfall sequence for intrinsic blood clotting. J. Clin. Invest. 1964, 43, 1310–1312. [CrossRef] [PubMed]

57. Ferreira, C.N.; Sousa, M.O.; Dusse, L.M.S.; Carvalho, M.G. A cell-based model of coagulation and its implications. Rev. Bras. Hematol. Hemoter. 2010, 32, 416–421. [CrossRef]

58. Dohan, D.M.; Choukroun, J.; Diss, A.; Dohan, S.L.; Dohan, A.J.J.; Mouhyi, J.; Gogly, B. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part II: Platelet-related biologic features. Oral Surg. Oral Med. Oral Pathol. Oral Radiol Endodontology 2006, 101, e45–e50. [CrossRef] [PubMed]

59. Van Hinsbergh, V.W.M.; Collen, A.; Koolwijk, P. Role of fibrin matrix in angiogenesis. Ann. N. Y. Acad. Sci. 2001, 936, 426–437. [CrossRef] [PubMed]

60. Rodríguez, G.; Fabris, V.; Mallmann, F.; Rech, C.A.; Carvalho, R.V.; Ruschel, G.H. Fibrinas Ricas em Plaquetas, Uma Alternativa para Regeneração Tecidual: Revisão de Literatura. J. Oral Investig. 2015, 4, 57–62. [CrossRef]

61. Khurshid, Z.; Asiri, F.Y.I.; Najeeb, S.; Ratnayake, J. The Impact of Autologous Platelet Concentrates on the Periapical Tissues and Root Development of Replanted Teeth: A Systematic Review. Materials 2022, 15, 2776. [CrossRef]

62. Choukroun, J.; Adda, F.; Schoeffler, C.; Vervelle, A. An opportunity in perio-implantology: The PRF. Implantodontie 2001, 42, 55–62.

63. Sahu, K.; Jadhav, S.; Khan, S.S.n.; Singh, N.; Khan, M.; Agarwal, A. Choukroun’s platelet-rich fibrin (L-PRF): A benevolence to surgical and reconstructive dentistry. Int. J. Oral Care Res. 2020, 8, 45. [CrossRef]

64. da Silva, L.M.P.; Sávio, D.D.S.F.; de Avila, F.C.; Vicente, R.M.; Reis, G.G.D.; Denardi, R.J.; da Costa, N.M.M.; Silva, P.H.F.; de Almeida Barros Mourão, C.F.; Miron, R.J.; et al. Comparison of the effects of platelet concentrates produced by high and low-speed centrifugation protocols on the healing of critical-size defects in rat calvaria: A microtomographic and histomorphometric study low-speed centrifugation protocols on the h. Platelets 2022, 1–10. [CrossRef]
88. Luca, R.E.; Giuliani, A.; Mănescu, A.; Heredea, R.; Hoinoiu, B.; Constantin, G.D.; Duma, V.-E.; Todea, C.D. Osteogenic Potential of Bovine Bone Graft in Combination with Laser Photobiomodulation: An Ex Vivo Demonstrative Study in Wistar Rats by Cross-Linked Studies Based on Synchrotron Microtomography and Histology. *Int. J. Mol. Sci.* **2020**, *21*, 778. [CrossRef] [PubMed]

89. Borges, R.M.M.; Cardoso, D.S.; Flores, B.C.; da Luz, R.D.; Machado, C.R.; Cerveira, G.P.; Dainty, R.B.; Dohnert, M.B. Effects of different photobiomodulation dosimetry on temporomandibular dysfunction: A randomized, double-blind, placebo-controlled clinical trial. *Lasers Med. Sci.* **2018**, *33*, 1859–1866. [CrossRef] [PubMed]

90. Pinheiro, A.L.; Gerbi, M.E. Photoengineering of bone repair processes. *Photomed Laser Surg.* **2006**, *24*, 169–178. [CrossRef] [PubMed]

91. Colombo, E.; Signore, A.; Aicardi, S.; Zekiy, A.; Utyuzh, A.; Benedicenti, S.; Amaroli, A. Experimental and Clinical Applications of Red and Near-Infrared Photobiomodulation on Endothelial Dysfunction: A Review. *Biomedicines* **2021**, *9*, 274. [CrossRef] [PubMed]

92. Mendes, C.; Dos Santos Haupenthal, D.P.; Zaccaron, R.P.; de Bem Silveira, G.; Corrêa, M.E.A.B.; de Roch Casagrande, L.; de Sousa Mariano, S.; de Souza Silva, J.I.; de Andrade, T.A.M.; Feuser, P.E.; et al. Effects of the Association between Photobiomodulation and Hyaluronic Acid Linked Gold Nanoparticles in Wound Healing. *ACS Biomater. Sci. Eng.* **2020**, *6*, 5132–5144. [CrossRef] [PubMed]

93. Tripodi, N.; Corcoran, D.; Antonello, P.; Balic, N.; Caddy, D.; Knight, A.; Meehan, C.; Sidiroglou, F.; Fraser, S.; Kiatos, D.; et al. The effects of photobiomodulation on human dermal fibroblasts in vitro: A systematic review. *J. Photochem. Photobiol. B* **2021**, *214*, 112100. [CrossRef] [PubMed]

94. Cios, A.; Ciepielak, M.; Szymański, Ł.; Lewicka, A.; Cieriak, S.; Stankiewicz, W.; Mendrycka, M.; Lewicki, S. Effect of Different Wavelengths of Laser Irradiation on the Skin Cells. *Int. J. Mol. Sci.* **2021**, *22*, 2437. [CrossRef] [PubMed]

95. Ailioaie, L.M.; Litscher, G. Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma. *Int. J. Mol. Sci.* **2020**, *21*, 7150. [CrossRef] [PubMed]

96. Kumar Rajendran, N.; George, B.P.; Chandran, R.; Tyng, I.M.; Houreld, N.; Abrahame, H. The Influence of Light on Reactive Oxygen Species and NF-κB in Disease Progression. *Antioxidants* **2019**, *8*, 640. [CrossRef] [PubMed]

97. Spannbauer, A.; Mester-Tonczar, J.; Traxler, D.; Kastner, N.; Zlabinger, K.; Hašimbegović, E.; Riesenhuber, M.; Pavo, N.; Goliash, G.; Gyöngyösi, M. Large Animal Models of Cell-Free Cardiac Regeneration. *Biomolecules* **2020**, *10*, 1392. [CrossRef] [PubMed]

98. Inchingolo, F.; Hazballa, D.; Inchingolo, A.D.; Malcangi, G.; Marinelli, G.; Mancini, A.; Maggiore, M.E.; Bordea, I.R.; Scarano, A.; Farronato, M.; et al. Innovative Concepts and Recent Breakthrough for Engineered Graft and Constructs for Bone Regeneration: A Literature Systematic Review. *Materials* **2022**, *15*, 1120. [CrossRef] [PubMed]

99. Chaudary, S.; Karner, L.; Weidinger, A.; Meixner, B.; Rieger, S.; Metzger, M.; Zipperle, J.; Dungel, P. In vitro effects of 635 nm photobiomodulation under hypoxia/reoxygenation culture conditions. *J. Photochem. Photobiol. B* **2020**, *209*, 111935. [CrossRef]

100. Dos Santos Ferreira, F.; Cadona, F.C.; Aurélio, A.R.; de Oliveira Martins, T.N.; Pivetta, H.M.F. Photobiomodulation-blue and red LED: Protection or cellular toxicity? In vitro study with human fibroblasts. *Lasers Med. Sci.* **2022**, *37*, 523–530. [CrossRef] [PubMed]